Zimmer Biomet Holdings Stock Current Asset
| ZBH Stock | USD 102.38 0.56 0.55% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Zimmer Biomet's long-term financial health and intrinsic value.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Zimmer Biomet Holdings Company Current Asset Analysis
Zimmer Biomet's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Zimmer Biomet Current Asset | 5.85 B |
Most of Zimmer Biomet's fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Zimmer Biomet Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
In accordance with the recently published financial statements, Zimmer Biomet Holdings has a Current Asset of 5.85 B. This is 172.03% higher than that of the Health Care Equipment & Supplies sector and 192.76% higher than that of the Health Care industry. The current asset for all United States stocks is 37.31% higher than that of the company.
Zimmer Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Zimmer Biomet's direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Zimmer Biomet could also be used in its relative valuation, which is a method of valuing Zimmer Biomet by comparing valuation metrics of similar companies.Zimmer Biomet is currently under evaluation in current asset category among its peers.
Zimmer Fundamentals
| Return On Equity | 0.0725 | ||||
| Return On Asset | 0.0465 | ||||
| Profit Margin | 0.12 % | ||||
| Operating Margin | 0.23 % | ||||
| Current Valuation | 26.37 B | ||||
| Shares Outstanding | 197.84 M | ||||
| Shares Owned By Insiders | 0.14 % | ||||
| Shares Owned By Institutions | 93.97 % | ||||
| Number Of Shares Shorted | 6.28 M | ||||
| Price To Earning | 77.41 X | ||||
| Price To Book | 1.63 X | ||||
| Price To Sales | 2.66 X | ||||
| Revenue | 7.68 B | ||||
| Gross Profit | 5.5 B | ||||
| EBITDA | 2.25 B | ||||
| Net Income | 905.2 M | ||||
| Cash And Equivalents | 375.7 M | ||||
| Cash Per Share | 2.71 X | ||||
| Total Debt | 6.2 B | ||||
| Debt To Equity | 0.48 % | ||||
| Current Ratio | 1.98 X | ||||
| Book Value Per Share | 62.62 X | ||||
| Cash Flow From Operations | 1.5 B | ||||
| Short Ratio | 2.96 X | ||||
| Earnings Per Share | 4.43 X | ||||
| Price To Earnings To Growth | 1.27 X | ||||
| Target Price | 122.35 | ||||
| Number Of Employees | 17 K | ||||
| Beta | 0.85 | ||||
| Market Capitalization | 20.14 B | ||||
| Total Asset | 21.37 B | ||||
| Retained Earnings | 11.1 B | ||||
| Working Capital | 2.22 B | ||||
| Current Asset | 5.85 B | ||||
| Current Liabilities | 1.62 B | ||||
| Annual Yield | 0.01 % | ||||
| Five Year Return | 0.75 % | ||||
| Net Asset | 21.37 B | ||||
| Last Dividend Paid | 0.96 |
About Zimmer Biomet Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Zimmer Biomet Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zimmer Biomet using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zimmer Biomet Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Zimmer Biomet Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zimmer Biomet's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zimmer Biomet Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zimmer Biomet Holdings Stock:Check out Zimmer Biomet Piotroski F Score and Zimmer Biomet Altman Z Score analysis. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Medical Equipment space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zimmer Biomet. If investors know Zimmer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zimmer Biomet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Zimmer Biomet Holdings is measured differently than its book value, which is the value of Zimmer that is recorded on the company's balance sheet. Investors also form their own opinion of Zimmer Biomet's value that differs from its market value or its book value, called intrinsic value, which is Zimmer Biomet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zimmer Biomet's market value can be influenced by many factors that don't directly affect Zimmer Biomet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zimmer Biomet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zimmer Biomet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zimmer Biomet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.